APP下载

Efficacy of intravitreal injection of ranibizumab in the treatment of macular edema secondary to non-ischemic branch retinal vein occlusion

2020-04-03JueLiuZaiHongChen

Journal of Hainan Medical College 2020年2期

Jue Liu, Zai-Hong Chen

Chongqing University Center Hospital, Chongqing Emergency Medical Center, Chongqing Fourth People’s Hospital, Ophthalmology, Chongqing 400014, China

Keywords:

ABSTRACT

1. Introduction

Retinal vein occlusion (RVO) is a common retinal vascular disease in ophthalmology [1]. Macular edema(ME) can be secondary to retinal and optic disc neovascularization, vitreous volume blood,neovascular glaucoma and so on. ME is one of the main causes of visual impairment in RVO patients [2]. RVO can lead to retinal ischemia and hypoxia in blocking area, resulting in the increase of vascular endothelial growth factor (VEGF), and the incidence of ME is greatly increased [3]. Anti-VEGF drugs are the research hotspots in the treatment of ME secondary to RVO and the inhibition of neovascularization in recent years [4,5]. Ranibizumab belongs to recombinant anti-VEGF monoclonal antibody fragment,which can regulate the blood visual omentum barrier, reduce vascular permeability, promote the absorption of retinal fluid and improve the effect of ME [6]. In this paper, the best corrected visual acuity ((BCVA), intraocular pressure (IOP), (central retinal thickness(CRT), central macular volume (CMV) and EN FACE were compared in patients with non-ischemic BRVO before and after vitreous injection of Ranibizumab. The results are reported as follows.

2. Materials and methods

2.1 Materials

From May 2018 to April 2019, 27 patients (27 eyes) with ME secondary to non-ischemic BRVO were selected as the experimental group, including 12 males and 15 females with an average age of 67. 37 ±8.63 years old, 20 normal subjects (20 eyes) served as control group, including 9 males and 11 females. The criteria for inclusion in the experimental group were as follows: ① according to the diagnostic criteria of ME secondary to non-ischemic BRVO[7]: blurred visual objects or visual field defects, tortuous dilatation of blocked branches of fundus, flame hemorrhage and yellowwhite exudation in vein distribution area, delayed filling of blocked veins, hemorrhage and exudation forming flake fluorescence in FFA, and no neovascularization and no perfusion area in ME,. OCT examination showed retinal diffusely edema or cystoid edema. ②OCT showed that the follow-up time of CRT > 300 μ m. ③ Followup time was ≥ 6 months; ④ the data of the cases were preserved completely; ⑤ the study was understood after communication and volunteered to join the study. Exclusion criteria: ① patients with binocular diseases; ② there were other eye diseases, history of ocular injury and operation before suffering from macular edema secondary to non-ischemic BRVO; ③ patients with chronic diseases such as diabetes mellitus and hypertension had a course of more than 10 years, and healthy eyes had found related fundus lesions by examination; ④ there was a history of cerebral infarction and myocardial infarction in the near future. The inclusion criteria of the normal control group were as follows: ① from 50 years old to 70 years old years old, male and female; ② routine examination excluding eye diseases (slit lamp microscope, direct ophthalmoscope and 90D front lens examination); ③ uncorrected visual acuity(UCVA) ≥ 1.0; ④ after communication, understanding the study and volunteering to join the study. Exclusion criteria: ① there were ametropia, other ophthalmopathy, history of eye injury and operation;② chronic diseases such as diabetes mellitus, hypertension and so on. In this study, the Helsinki Declaration was complied with and approved by the Ethics Committee of the Chongqing University Center Hospital. The patients and subjects participating in the study signed informed consent forms.

2.2 Methods

2.2.1

Inspection method Before and after treatment in the experimental group, the patients in the experimental group were examined by standard logarithmic distant visual acuity table and comprehensive optometer before and 1wk, 1 mo, 2 mo, 3 mo and 6mo respectively.IOP, slit lamp was used to examine the anterior segment of the eye,90D anterior lens and fluorescein fundus angiography were used to examine the fundus, and optical coherence tomography scanner was used for CRT, CMV and EN FACE. 20 normal control subjects were examined by standard logarithmic remote UCVA. IOP, slit lamp was used to examine the anterior segment of the eye, 90D anterior lens and fluorescein fundus angiography were used to examine the fundus. CRT and CMV were examined by optical coherence tomography at 1wk, 1mo, 3mo and 6mo on the day of admission.CRT refers to the average distance from the inner limiting membrane to the outer surface of the pigment epithelial layer in the diameter of the 1.0mm region centered on the central fovea.; CMV refers to the structure of the polar retinal tissue after; EN FACE examination of the volume from the inner limiting membrane to the outer surface of the pigment epithelial layer in the diameter 6.0mm region centered on the central fovea. If the strength of the detection signal is less than 6 ≤ 10, the measurement will be carried out again. Each inspection is carried out by the same inspector.

2.2.2

Anti-VEGF treatment There was no absolute taboo before treatment. Patients were informed of the possible risk of intravitreal injection of anti-VEGF drugs, obtained their consent and signed an informed consent form for the operation. Rinse the lacrimal passage of both eyes before operation and use levofloxacin eye drops 3 days in advance, 4 times a day. Operation of aseptic laminar flow operating room, routine disinfection, towel laying, 0.5% promethaine eye drops, 5min/ times, a total of three times. 50 g / L povidone iodine solution disinfected the conjunctival capsule for 3 min, and the conjunctival capsule was fully washed with 20 mL BSS solution,and the needle tip pointed to the center of the eyeball at the superior temporal or upper nasal distance from the scleral edge of the angle and scleral edge into the vertical needle, and the tip of the needle pointed to the center of the eyeball. After injecting Ranibizumab 0.05mL into vitreous cavity, aseptic cotton swab was pressed into the needle site for 20 s. Manual visual acuity was found in the eyes examined, and sterile dressing was bandaged after application of tobramycin dexamethasone eye ointment. All patients were treated with vitreous cavity injection by the same operator.

The visual acuity of the affected eyes was monitored 2 hours after operation, and the anterior segment was examined by IOP, slit lamp.If the intraocular pressure of the affected eyes was significantly higher than that before operation, the patients were given oral acetate methazolamide 50 mg. Visual acuity, intraocular pressure, slit lamp examination of anterior segment and 90D anterior lens were examined on the first day after operation, and levofloxacin eye drops were continued for 7 days.

2.2.3

Treatment prescription All 27 patients were treated with a 3-PRN regimen, a 1-month, continuous 3 mo, and then on-demand, and the standard[8] for the on-demand dosing was that the ME was still not resolved and the CRT was more than 300 μm, and the injection drug and dose were consistent with the first treatment. The BCVA,IOP, anterior segment examination, fundus examination and OCT were examined by 1 wk, 1 mo, 2 mo, 3 mo and 6 mo after the first treatment.

2.2.4 Criteria for judging curative effect[9]The results of the BCVA and OCT examinations were used as the index of the efficacy evaluation after the completion of the treatment.Effective: after the operation, the BCVA was increased by 2 lines or more, and the OCT examination showed that the ME was all resolved; effective: after the post-operation BCVA was increased by less than 2 lines, the OCT examination showed that the ME had resolved; it was not effective: the BCVA was not recovered or even decreased after the operation, and the OCT examination showed no significant change in the ME. The success rate of treatment is:(number of effective patients)/ total number of patients.

2.3 Statistical method SPSS 21.0 statistical software is used for data statistical processing.

Age, IOP, BCVA and CRT, CMV were expressed by mean±standard deviation (±s). Two independent sample t tests were used to compare the two groups at each time point, and the matched t test was used to compare the experimental group before and after treatment (P < 0.05).

3. Results

General the average age of the patients in the experimental group was (67. 5%). The times of vitreous injection were (3.26 ±0.59)years old and (3.26 ±0.59) times, respectively, and there was no significant difference in 3mo and 6mo between the two groups at 1wk, 1mo and 2mo after treatment (all P > 0.05), and there was no significant difference between the two groups (all P > 0.05), and there was no significant difference between the two groups (P >0.05).

Table.1 Comparison of in experimental group before and after treatment at 1wk, 1mo,2mo, 3mo and 6mo IOP(mmHg)

3.1 BCVA before and after treatment

The BCVA of the experimental group was significantly higher than that of the control group (P < 0.0001).

Table.2 Comparison of in experimental group before and after treatment at 1wk, 1mo,2mo, 3mo and 6mo BCVA

3.2 CRT before and after treatment

The CRT of the experimental group was significantly lower than that of the control group (P < 0.01) at the 1wk, 1mo, 2mo, 3mo and 6mo after intravitreal injection of Ranibizumab, and the difference was statistically significant (P < 0.05) at 1wk, 1mo, 2mo and 3mo after treatment, and there was no statistical difference at 6mo after treatment (P > 0.05).

Table.3 Comparison of in experimental group before and after treatment at 1wk, 1mo,2mo, 3mo and 6mo CRT(μm)

3.3 CMV before and after treatment

CMV in the experimental group was significantly lower than that in the control group (P < 0.01) at 1wk, 1mo, 2mo, 3mo and 6mo after intravitreal injection of a Ranibizumab, and the difference was statistically significant (P < 0.05) at 1wk, 1mo, 2mo and 3mo after treatment, and there was no statistical difference at 6mo after treatment (P > 0.05).

Table.4 Comparison of in experimental group before and after treatment at 1wk, 1mo,2mo, 3mo and 6mo CMV(mm3)

3.4 Treatment success rate

After 3 PRN intravitreal injection of anti-Leizumab in the experimental group, 19 eyes were effective, 4 eyes were effective and 4 eyes were ineffective. The success rate of treatment was 85.19%.

3.5 Before and after treatment in the experimental group,1 month, 1 month, 2 months, 3 months, 6 mo EN FACE images (Figure.1)

Figure.1 Patient Li, female, 56 years old, left eye BRVO secondary ME,before and 1 PRN intravitreal injection Ranibizumab before and 1 month, 1 mo, 2 mo, 3 mo and 6mo after treatment EN FACE images

3.6 Intraoperative and post-operative complications

There were 3 eyes with subconjunctival hemorrhage, full absorption after 1 week of injection, no endophthalmitis, persistent high intraocular pressure, vitreous hemorrhage, retinal detachment and other ocular complications as well as serious systemic complications.

4. Discussion

RVO is the second-largest retinal vascular disease after diabetic retinopathy, and its pathogenesis is not clear. It is widely believed that it is embolic, vascular wall degeneration and hemodynamic changes [10]. According to the blocking site, it can be divided into the central retinal vein occlusion, the retinal branch vein occlusion and the half-side vein occlusion. The most common is the BRVO.According to the ischemia, it can be divided into the ischemic type and the non-ischemic type. The results show that [11], the ME is the first complication of BRVO, the incidence rate is as high as 46.7%,and the second is the new blood vessel and related complications.The persistent ME can cause the photoreceptors of the macular region to be seriously damaged, and eventually lead to irreversible damage of the central vision.

Macular grid laser photocoagulation, intravitreal injection of anti-VEGF drugs and corticosteroids are the main methods for the treatment of ME secondary to RVO. Macular grid laser photocoagulation is a classic treatment for RVO combined with ME,but the American BRVO team found that BRVO patients should take other treatments first [12], and then consider macular grid laser photocoagulation after 3 months of illness, which greatly limits its clinical application [13]. In addition, triamcinolone acetonide is a common corticosteroid injected into vitreous cavity. Triamcinolone acetonide significantly alleviated ME [14] and improved visual acuity[15]. However, the drug may lead to increased intraocular pressure,cataract, endophthalmitis, vitreous blood, retinal detachment and retinal toxicity, among which elevated intraocular pressure is the most common. In recent years, with the emergence of safer and more effective anti-VEGF drugs and dexamethasone sustainedrelease agents, the clinical application of triamcinolone acetonide is becoming more and more limited [16]. When BRVO occurs, retinal capillary pressure increases, vascular permeability increases, fluid leakage to the outer plexiform layer forms ME;, retinal ischemia and hypoxia lead to the increase of VEGF, and the integrity of bloodretinal barrier is destroyed. The level of VEGF in eyes was negatively correlated with BCVA, but positively correlated with the degree of ME [17]. Feng et al. [18] showed that the levels of inflammatory factors VEGF and IL-6 were closely related to the severity of ME,in which VEGF-A was the key cytokine leading to vascular leakage ME. Therefore, vitreous injection of anti-VEGF drugs has become the first choice for the treatment of ME secondary to RVO in recent years [19]. Ranibizumab, bevacizumab, Compassie, Abersip and so on are commonly used anti-VEGF drugs at present. Ranibizumab is a synthetic Fab fragment of monoclonal anti-VEGF antibody,which can selectively antagonize the binding of VEGF-A to VEGF,decrease the expression of VEGF, inhibit neovascularization and promote its regression, so as to reduce vascular leakage and improve macular edema. In this study, 27 patients with ME secondary to BRVO were treated with 3 PRN intravitreal injection of Ranibizumab, BCVA was significantly increased, CRT and CMV were significantly decreased, and the success rate of treatment was 85.19%. Meta-analysis abroad showed that continuous injection of Ranibizumab into vitreous cavity could significantly reduce the retinal thickness in macular area[20], which was consistent with the results of this study. Therefore, we believe that intravitreal injection of Ranibizumab is effective in the treatment of ME secondary to ischemic BRVO.

ENFACE, also known as the C-SCAN scan, clearly reflects the structure of the various layers of the posterior polar retinal tissue. In order to detect and observe the extent and extent of lesions in time and intuitively, it is beneficial to the early diagnosis of disease, the analysis of progress and the evaluation of therapeutic prognosis.Fig.1 Patient Li C-SCAN scan showed macular protuberance and macular retinal edema thickening before treatment. Diffuse edema in each layer of retina, the inner nuclear layer, the outer plexiform layer and the outer nuclear layer are more common. Especially in the outer plexiform layer, the photoreceptor ellipsoid zone also showed loose and edema, consistent with the reports at home and abroad[21,22]. the macular thickness of 1 wk,1 mo,2 mo,3 mo and 6 mo gradually decreased to normal, retinal edema subsided, cystic cavitylike changes gradually disappeared, and the interlayer structure of elliptical body band gradually recovered after the patients were treated with 3 prn intravitreal injection of anti-lazumab. Therefore,we believe that ENFACE can be used as an effective means to evaluate the severity and treatment prognosis of patients with ischemic BRVO secondary ME in clinical work.

Foreign studies have shown that intravitreal injection of anti-VEGF drugs may lead to eye and systemic complications [23]. Eye complications include lens injury, endophthalmitis, retinal pigment epithelial tear and arterial occlusion. Systemic complications include hypertension, arterial thrombosis and cardiovascular disease in elderly patients. In this study, only 3 eyes had subconjunctival bleeding, which had been completely absorbed at the time of revisit one week after injection, and no serious complications of the eyes and the whole body had occurred. The reasons were as follows: in this study, all patients were treated with vitreous cavity injection by the same operator, which avoided the injury caused by unskilled operation.Patients with a long course of diabetes, hypertension,recent history of cerebral infarction and myocardial infarction were excluded, and the underlying diseases of the whole body might be relatively mild. At the same time, the follow-up time was short and the sample size was small, so there were no possible long-term complications for the time being.

The results of this study showed that the ME gradually disappeared or significantly decreased in most patients after treatment with vitreous intravitreous injection of Leizumab, and the increase of vision and CRT decreased significantly, but the visual acuity recovery and CRT decrease were not obvious in some individual patients, which may be related to the age, course and sensitivity to drug. Because of the small sample size and short follow-up time,the safety and effectiveness of the long-term application of the drug will be expanded in the future study, and the follow-up time will be extended, so as to evaluate the therapeutic effect more objectively and accurately.


登录APP查看全文